(Q43234572)

16 November 2017

title

Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness (English)

1 reference

16 November 2017

1 reference

Karin Nilsson

1

1 reference

16 November 2017

Lars Gustafson

series ordinal

2

1 reference

16 November 2017

Michael Nornholm

series ordinal

3

1 reference

16 November 2017

Björn Hultberg

series ordinal

4

1 reference

16 November 2017

publication date

1 January 2010

1 reference

Clinical Chemistry and Laboratory Medicine

16 November 2017

published in

1 reference

16 November 2017

volume

48

1 reference

16 November 2017

issue

1

1 reference

16 November 2017

page(s)

129-135

1 reference

Apolipoprotein E: far more than a lipid transport protein

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Apolipoprotein E and atherosclerosis: insight from animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Identification of cognitive impairment in the elderly: homocysteine is an early marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Facts and recommendations about total homocysteine determinations: an expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Plasma homocysteine and vascular disease in psychogeriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Plasma homocysteine, cobalamin/folate status, and vascular disease in a large population of psychogeriatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Hematologic risk factors of vascular disease and their relation to dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Cardiovascular Risk Factors for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Plasma homocysteine and vascular disease in elderly patients with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine, cystatin C and N-terminal-pro brain natriuretic Peptide. Vascular risk markers in elderly patients with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

C-reactive protein: vascular risk marker in elderly patients with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Homocysteine and cognitive performance: modification by the ApoE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Vascular factors predict rate of progression in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Clinical significance of silent cerebral infarctions in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Coexisting cerebral infarction in Alzheimer's disease is associated with fast dementia progression: applying the National Institute for Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Apolipoprotein E epsilon4 allele is associated with vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2010.013

21 January 2018

Identifiers

DOI

10.1515/CCLM.2010.013

1 reference

16 November 2017

1 reference